In this episode of the Diabetes Innovators Series, Rob interviews Dr. Anath Shalev discussing the recent advancements in TIXiMed's TIX100, an oral therapy for type 1 diabetes. The conversation covers the successful completion of a phase one study, the implications of the results, and the potential impact of TIX100 on diabetes management. Dr. Shalev emphasizes the importance of addressing beta cell dysfunction and the exciting metabolic signals observed during the study. The discussion also touches on the future directions for TIX100 and its role in improving the lives of diabetes patients.
Chapters
00:00 Introduction to TixiMed and TIX100
01:16 Phase One Study Results and Implications
05:22 Metabolic Signals and Future Studies
08:11 The Role of TIX100 in Diabetes Management
09:47 Future Directions and Patient Impact
Resources:
